Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

NCT05491083 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor
Triple Negative Breast Cancer

Interventions

DRUG: Pembrolizumab & ADG106 (Phase Ib)
DRUG: Pembrolizumab & ADG106 (Phase II)

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]
[object Object]